Author

L. Donvovan

Observed name: L Donvovan

OpenAlex ID: A5089068374

HTA5 Variation in Health Technology Assessments for Nivolumab Plus Chemotherapy Vs Chemotherapy in First-Line Gastric Cancer

2023 · D. Bertwistle, P. Casabianca, et al. · Value in Health

Cost Effectiveness Analysis (CEA) of Nivolumab in 2nd Line Non-Small Cell Lung Cancer (NSCLC) with Non-Squamous Histology (NSQ) Using A Mixed Comparator of Docetaxel and Pemetrexed in An Australian Setting

2017 · L Donvovan, H Kim · Value in Health

Works count: 2

Citation count:

H-index:

I10-index: